Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of Nivolumab with Radiotherapy in Esophageal Cancer (INEC)
NCT03544736Phase 2Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- Apr 2018
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in esophageal cancer, sponsored by Oslo University Hospital. Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03544736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544736.